tiprankstipranks
Intellia Therapeutics Inc (NTLA)
NASDAQ:NTLA
US Market
NTLA
Intellia Therapeutics
RESEARCH TOOLSreports
Want to see NTLA full AI Analyst Report?

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

4,836 Followers
See the Price Targets and Ratings of:

NTLA Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
9 Buy
8 Hold
2 Sell
Based on 19 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NTLA Stock 12 Month Forecast

Average Price Target

$21.06
▲(40.89% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $21.06 with a high forecast of $49.00 and a low forecast of $8.00. The average price target represents a 40.89% change from the last price of $14.95.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","17":"$17","28":"$28","39":"$39","50":"$50"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.0625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,17,28,39,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.26,16.00923076923077,18.75846153846154,21.50769230769231,24.25692307692308,27.00615384615385,29.755384615384614,32.504615384615384,35.253846153846155,38.003076923076925,40.752307692307696,43.501538461538466,46.25076923076923,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.26,13.860192307692307,14.460384615384616,15.060576923076923,15.66076923076923,16.260961538461537,16.861153846153847,17.461346153846154,18.06153846153846,18.66173076923077,19.261923076923075,19.862115384615386,20.462307692307693,{"y":21.0625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.26,12.855384615384615,12.45076923076923,12.046153846153846,11.641538461538461,11.236923076923077,10.832307692307692,10.427692307692308,10.023076923076923,9.618461538461538,9.213846153846154,8.80923076923077,8.404615384615385,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$49.00Average Price Target$21.06Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on NTLA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$30→$25
Buy
67.22%
Upside
Reiterated
05/13/26
Intellia Therapeutics price target lowered to $25 from $30 at H.C. WainwrightIntellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Morgan Stanley Analyst forecast on NTLA
Terence Flynn
Morgan Stanley
Morgan Stanley
$15
Hold
0.33%
Upside
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), TriSalus Life Sciences (NASDAQ: TLSI) and Fractyl Health, Inc. (NASDAQ: GUTS)
J.P. Morgan Analyst forecast on NTLA
Brian Cheng
J.P. Morgan
J.P. Morgan
$8
Sell
-46.49%
Downside
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Bernstein Analyst forecast on NTLA
William Pickering
Bernstein
Bernstein
$13→$17
Hold
13.71%
Upside
Assigned
05/13/26
Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein
Wedbush Analyst forecast on NTLA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$12
Hold
-19.73%
Downside
Reiterated
05/12/26
Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
Canaccord Genuity Analyst forecast on NTLA
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$58→$49
Buy
227.76%
Upside
Reiterated
05/12/26
Intellia Therapeutics price target lowered to $49 from $58 at CanaccordIntellia Therapeutics price target lowered to $49 from $58 at Canaccord
Wells Fargo Analyst forecast on NTLA
Yanan Zhu
Wells Fargo
Wells Fargo
$15
Hold
0.33%
Upside
Reiterated
05/12/26
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
Bank of America Securities Analyst forecast on NTLA
Alec Stranahan
Bank of America Securities
Bank of America Securities
$20→$19
Hold
27.09%
Upside
Reiterated
05/12/26
Intellia Therapeutics price target lowered to $19 from $20 at BofAIntellia Therapeutics price target lowered to $19 from $20 at BofA
William Blair Analyst forecast on NTLA
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/11/26
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
TD Cowen Analyst forecast on NTLA
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE), Intellia Therapeutics (NASDAQ: NTLA) and Corvus Pharmaceuticals (NASDAQ: CRVS)
Goldman Sachs Analyst forecast on NTLA
Salveen Richter
Goldman Sachs
Goldman Sachs
$9
Sell
-39.80%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Perspective Therapeutics (NYSE MKT: CATX)
RBC Capital Analyst forecast on NTLA
Luca Issi
RBC Capital
RBC Capital
$15
Hold
0.33%
Upside
Reiterated
05/11/26
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Citizens JMP Analyst forecast on NTLA
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$28→$30
Buy
100.67%
Upside
Reiterated
04/28/26
Intellia Therapeutics price target raised to $30 from $28 at CitizensIntellia Therapeutics price target raised to $30 from $28 at Citizens
Evercore ISI Analyst forecast on NTLA
Jonathan Miller
Evercore ISI
Evercore ISI
$16
Hold
7.02%
Upside
Reiterated
04/28/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Intellia Therapeutics (NASDAQ: NTLA) and Incyte (NASDAQ: INCY)
JonesTrading Analyst forecast on NTLA
Debanjana Chatterjee
JonesTrading
JonesTrading
$29
Buy
93.98%
Upside
Reiterated
04/27/26
Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on NTLA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$30→$25
Buy
67.22%
Upside
Reiterated
05/13/26
Intellia Therapeutics price target lowered to $25 from $30 at H.C. WainwrightIntellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Morgan Stanley Analyst forecast on NTLA
Terence Flynn
Morgan Stanley
Morgan Stanley
$15
Hold
0.33%
Upside
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), TriSalus Life Sciences (NASDAQ: TLSI) and Fractyl Health, Inc. (NASDAQ: GUTS)
J.P. Morgan Analyst forecast on NTLA
Brian Cheng
J.P. Morgan
J.P. Morgan
$8
Sell
-46.49%
Downside
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Bernstein Analyst forecast on NTLA
William Pickering
Bernstein
Bernstein
$13→$17
Hold
13.71%
Upside
Assigned
05/13/26
Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein
Wedbush Analyst forecast on NTLA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$12
Hold
-19.73%
Downside
Reiterated
05/12/26
Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
Canaccord Genuity Analyst forecast on NTLA
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$58→$49
Buy
227.76%
Upside
Reiterated
05/12/26
Intellia Therapeutics price target lowered to $49 from $58 at CanaccordIntellia Therapeutics price target lowered to $49 from $58 at Canaccord
Wells Fargo Analyst forecast on NTLA
Yanan Zhu
Wells Fargo
Wells Fargo
$15
Hold
0.33%
Upside
Reiterated
05/12/26
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
Bank of America Securities Analyst forecast on NTLA
Alec Stranahan
Bank of America Securities
Bank of America Securities
$20→$19
Hold
27.09%
Upside
Reiterated
05/12/26
Intellia Therapeutics price target lowered to $19 from $20 at BofAIntellia Therapeutics price target lowered to $19 from $20 at BofA
William Blair Analyst forecast on NTLA
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/11/26
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
TD Cowen Analyst forecast on NTLA
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE), Intellia Therapeutics (NASDAQ: NTLA) and Corvus Pharmaceuticals (NASDAQ: CRVS)
Goldman Sachs Analyst forecast on NTLA
Salveen Richter
Goldman Sachs
Goldman Sachs
$9
Sell
-39.80%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Perspective Therapeutics (NYSE MKT: CATX)
RBC Capital Analyst forecast on NTLA
Luca Issi
RBC Capital
RBC Capital
$15
Hold
0.33%
Upside
Reiterated
05/11/26
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Citizens JMP Analyst forecast on NTLA
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$28→$30
Buy
100.67%
Upside
Reiterated
04/28/26
Intellia Therapeutics price target raised to $30 from $28 at CitizensIntellia Therapeutics price target raised to $30 from $28 at Citizens
Evercore ISI Analyst forecast on NTLA
Jonathan Miller
Evercore ISI
Evercore ISI
$16
Hold
7.02%
Upside
Reiterated
04/28/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Intellia Therapeutics (NASDAQ: NTLA) and Incyte (NASDAQ: INCY)
JonesTrading Analyst forecast on NTLA
Debanjana Chatterjee
JonesTrading
JonesTrading
$29
Buy
93.98%
Upside
Reiterated
04/27/26
Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months
Mani ForooharLeerink Partners
Success Rate
15/39 ratings generated profit
38%
Average Return
+5.26%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of +5.26% per trade.
1 Year
Gena WangBarclays
Success Rate
10/26 ratings generated profit
38%
Average Return
-11.33%
Copying Gena Wang's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -11.33% per trade.
2 Years
Gena WangBarclays
Success Rate
8/26 ratings generated profit
31%
Average Return
-24.71%
Copying Gena Wang's trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -24.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NTLA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
2
6
10
12
Buy
5
3
5
4
5
Hold
22
13
22
15
19
Sell
1
0
1
2
4
Strong Sell
0
0
0
0
0
total
35
18
34
31
40
In the current month, NTLA has received 17 Buy Ratings, 19 Hold Ratings, and 4 Sell Ratings. NTLA average Analyst price target in the past 3 months is 21.06.
Each month's total comprises the sum of three months' worth of ratings.

NTLA Financial Forecast

NTLA Earnings Forecast

Next quarter’s earnings estimate for NTLA is -$0.81 with a range of -$0.95 to -$0.67. The previous quarter’s EPS was -$0.81. NTLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NTLA has Performed in-line its overall industry.
Next quarter’s earnings estimate for NTLA is -$0.81 with a range of -$0.95 to -$0.67. The previous quarter’s EPS was -$0.81. NTLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NTLA has Performed in-line its overall industry.

NTLA Sales Forecast

Next quarter’s sales forecast for NTLA is $13.15M with a range of $0.00 to $16.50M. The previous quarter’s sales results were $15.05M. NTLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NTLA has Performed in-line its overall industry.
Next quarter’s sales forecast for NTLA is $13.15M with a range of $0.00 to $16.50M. The previous quarter’s sales results were $15.05M. NTLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NTLA has Performed in-line its overall industry.

NTLA Stock Forecast FAQ

What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics Inc’s 12-month average price target is 21.06.
    What is NTLA’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics Inc has 40.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NTLA a Buy, Sell or Hold?
          Intellia Therapeutics Inc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 8 hold ratings and 2 sell ratings.
            What is Intellia Therapeutics Inc’s price target?
            The average price target for Intellia Therapeutics Inc is 21.06. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $49.00 ,the lowest forecast is $8.00. The average price target represents 40.89% Increase from the current price of $14.95.
              What do analysts say about Intellia Therapeutics Inc?
              Intellia Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of NTLA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.